
BeyondSpring Inc.
NASDAQ:BYSI
1.74 (USD) • At close March 14, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | BeyondSpring Inc. |
Symbool | BYSI |
Munteenheid | USD |
Prijs | 1.741 |
Beurswaarde | 70,146,876 |
Dividendpercentage | 0% |
52-weken bereik | 1.43 - 3.75 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Lan Huang Ph.D. |
Website | https://www.beyondspringpharma.com |
An error occurred while fetching data.
Over BeyondSpring Inc.
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and for treatment of later-stage non-small cell
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)